Compagnie Chargeurs Invest (CRI) Q4 2022 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2022 earnings summary
5 Nov, 2026Executive summary
Revenue reached €746.4m; like-for-like growth was 8.7% excluding Healthcare Solutions, with positive contributions from all businesses.
Recurring operating profit was €45.4m, down 10.5% reported YoY but up 41.7% excluding healthcare activities.
Strategic transformation continued through premiumization, growth in Luxury and targeted acquisitions.
Financial highlights
Revenue was €746.4m, up 1.3%; gross profit was €195.0m, up 4.7%, and gross margin was 26.1% vs 25.3%.
EBITDA was €67.9m vs €73.8m; recurring operating profit was €45.4m vs €50.7m.
Operating profit was €38.5m vs €41.2m; attributable net profit was €22.1m vs €30.6m, and EPS was €0.92 vs €1.30.
Net cash from operating activities was -€7.4m, including a €40.5m working-capital outflow; operating cash flow before working-capital changes was €32.9m.
Outlook and guidance
2023 priorities include leveraging Technologies leadership, converting Museum Studio’s order book into profits, accelerating synergies and pursuing a key Luxury acquisition.
Museum Studio expects 2023 revenue above €120m and a higher operating margin, particularly in H2.
Luxury is expected to exceed 30% of revenue in 2023; the stated target is to rapidly exceed €500m in Luxury revenue, including through acquisitions.
Leap Forward rollout is expected to support sustained revenue growth, high operating cash flow and a more balanced contribution from the two divisions.
2025 EBITDA targets are above €90m for Technologies and above €30m for Luxury, assuming a normalized macroeconomic environment.
Latest events from Compagnie Chargeurs Invest
- Strong cash generation and record order books set up growth after a 2021 rebound.CRI
Q4 2021 - Q3 returned to growth, with Asia and high-end platforms leading the acceleration.CRI
Q3 2026 - Transformation to high-luxury focus, Novacel sale, and €14/share buyback drive strong outlook.CRI
Q2 2026 - Q1 2026 revenue fell, but strategic transformation accelerates with Novacel divestment and strong order books.CRI
Q1 2026 - Novacel sale and strategic refocus boost financial flexibility and target €1bn NAV by 2030.CRI
Q4 2025 - Stable H1 2025 revenue and NAV growth, strong Museum Studio gains, Novacel disposal under review.CRI
Q2 2025 - Revenue up 11.1% and recurring operating profit up 33.9%, with strong cash flow and reduced net debt.CRI
Q2 2024 - Strong growth, strategic transformation, and all resolutions passed amid market and regulatory risks.CRI
AGM 2025 - Museum Studio and Personal Goods drove 5.6% revenue growth in Q1 2025 amid global challenges.CRI
Q1 2025